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The activating combination of CD2 antibodies Leu-5b plus 9.1 stimulates tyrosine phosphorylation in the human T cell line Jurkat. The tyrosine 
phosphorylation has the same molecular weight pattern as that seen when cells are stimulated on the CD3 receptor with OKT3 antibodies. These 
data provide evidence that signal transduction by the CD2 receptor is coupled to an increase in tyrosine phosphorylation that is similar to that 
coupled to the CD3 receptor. 
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1. INTRODUCTION 
Monoclonal antibodies against several different pro- 
teins present on the external surface of T lymphocytes 
have the ability to activate T cells. Among the proteins 
identified by these monoclonal antibodies are the CD2 
and CD3 receptors. The CD3 receptor is composed of 
several polypeptides that form a complex. The CD3 
complex interacts with the clonotypic polypeptides of 
the antigen receptor and there is considerable vidence 
that signal transduction through the antigen receptor is 
mediated by the CD3 complex [l]. Several studies sug- 
gest that signal transduction by CD2 also occurs, at 
least in part, via CD3. Signal transduction by CD2 re- 
quires the coexpression of CD3 [2-51 and stimulation 
of CD2 has been shown to activate the same second 
messengers ystems as are activated by the stimulation 
of CD3. Thus both receptors are linked to the activa- 
tion of the phosphatidyl inositol pathway with subse- 
quent increases in cell calcium and diacylglycerol and 
activation of protein kinase C [6-lo]. 
tyrosine protein kinases [12-151. The CD45 surface 
molecule has been identified as phosphotyrosine 
phosphatase [ 16,171. Since signal transduction by 
several T cell surface receptors involves the regulation 
of tyrosine phosphorylation it seemed likely that 
stimulation of the CD2 receptor would also result in 
changes in tyrosine phosphorylation. We have tested 
for the ability of monoclonal antibodies to CD2 to 
regulate tyrosine phosphorylation in the Jurkat cell 
line, a line frequently used for studies of T cell ac- 
tivation. 
2. EXPERIMENTAL 
Several T cell surface receptors have been found to 
be coupled to the regulation of tyrosine protein kinase 
activity, suggesting that tyrosine phosphorylation has 
an important role in T cell activation and proliferation. 
Activation of T cells through the antigen/CD3 receptor 
complex and the Thy1 receptor results in activation of 
a tyrosine protein kinase [9,11]. Signal transduction by 
the CD4 and CD8 receptors as well as the receptor for 
interleukin-2 (IL-2) also involves the activation of 
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The Jurkat 77 6.8 clone was obtained from Dr Kendall Smith, 
Dartmouth Medical College. CTLL-2 cells (ATCC) were used to 
assay for the production of IL-2. The CD3 antibody OKT3 was 
purified from the medium of the 0KT3 hybridoma (ATCC) using 
protein A Sepharose. The CD2 antibody 9.1 [l&19] was generously 
provided as an ascites fluid by Dr Soo Young Yang, Sloan Kettering 
Cancer Center, New York, NY. The CD2 antibody LeuSb was ob- 
tained from Becton Dickerson. Rabbit antibodies to phosphot~osine 
were produced as previously described 1151. Experiments examining 
levels of protein tyrosine phospho~lation were initiated by adding 
Jurkat cells (4 x lo6 in 0.5 ml) to tubes that contained either CD3 or 
CD2 antibodies. The concentrations of antibodies that were used 
were those that gave a maximal response as determined from 
preliminary experiments. Following incubation for the indicated 
times the cells were pelleted with a 30 s centrifugation. The pellets 
were immediately dissolved in SDS-sample buffer and placed in a 
boiling water bath for 5 min. Samples were subjected to SDS-gel elec- 
trophoresis following blotting onto nitrocellulose. Proteins contain- 
ing phosphotyrosine were detected by probing the blots with 
antibodies against phosphotyrosine followed by [rz51]protein A to 
detect the immune complexes [15,20]. CD3 was down modulated by 
incubating Jurkat cells for 16 h in the presence of 1 @g/ml 0KT3 an- 
tibodies. 
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3. RESULTS 
Initial experiments were performed to demonstrate 
the ability of CD2 antibodies to stimulate a 
physiological response such as IL-2 production in this 
Jurkat clone. Stimulation of the CD2 receptor by an- 
tibodies generally requires two different monoclonal 
antibodies that bind to distinct epitopes. An antibody 
such as LeuSb binds to an exposed epitope on CD2 but 
does not activate. However, LeuSb causes a conforma- 
tion change that exposes a second, otherwise cryptic 
epitope, that binds an activating monoclonal antibody 
such as 9.1 [l&19]. In concordance with this 
mechanism table 1 shows that Leu5b and 9.1 together 
stimulate IL-2 production while neither antibody alone 
is effective. Table 1 also shows that the CD3 antibody 
OKT3 induces IL-2 production in this Jurkat clone. Ac- 
tivation through either CD2 or CD3 has the similar re- 
quirement for costimulation with a phorbol ester. Thus 
this Jurkat clone expresses ignificant IeveIs of CD2 
and CD3 receptors that can generate signals that result 
in a common physiological response. The results in 
table 1 also confirm the ability of LeuSb to bind to CD2 
in such a manner as to expose the cryptic epitope for 
9.1 allowing for this activating antibody to bind and ac- 
tivate the CD2 receptor [18,19]. 
Fig.1 shows how CD2 antibodies affect the level of 
tyrosine phosphorylation in Jurkat cells. In the absence 
of any stimulus Jurkat cells have basal tyrosine 
phosphorylation in several bands, the most prominent 
having molecular weights of 56000, 62000, and 
115000. Treatment of these cells with the activating 
CD2 antibody 9.1 alone resulted in small but reproduci- 
ble increases in tyrosine phosphorylation of several of 
the bands present in the basal state. The nonactivating 
antibody Leu5b had little or no effect on the level of 
tyrosine phosphorylation. When LeuSb and 9.1 were 
added together large increases in tyrosine phosphoryla- 
tion were observed in bands with molecular weights of 
115000, 96000, 78000, 65000 and 42000. Smaller in- 
Table 1 
Effect of CD2 and CD3 antibodies on IL-2 production by clone 77 
6.8 Jurkat cells 
Condition IL-2 production (U/ml) 
Control 0 
9.1 0 
LeuSb 0 
9.1 + LeuSb 46 
OKT3 45 
OKT3 + 9.1 -t LeuSb 51 
A23187 37 
Jurkat cells were incubated with the various agents in the presence of 
100 nM phorbol myristic acetate. After 24 h the supernatants were 
collected and assayed for the presence of IL-2. None of the agents 
stimulated significant IL-2 production in the absence of phorbol 
myristic acetate. 
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Fig.1. Effect of CD2 antibodies 9.1 and LeuSb on tyrosine 
phosphorylation in Jurkat cells. Cells were untreated (C) or treated 
with either 9.1, LeuSb or 9.1 + LeuSb for the indicated times in 
minutes. At the end of each incubation period the cells were pelleted 
and processed for an immunoblot with antibodies to 
phosphotyrosine. The figure shows the autoradiogram of the blot. 
The arrowheads indicate th position of the major phosphotyrosine- 
containing proteins present in the absence of any stimulus. The 
arrows indicate the molecular masses in kDa of the proteins that 
undergo large increases in phosphotyrosine. 
creases in tyrosine phosphorylation were observed in 
the bands at 56000 and 62000. Thus while having no ef- 
fect by itself, LeuSb greatly potentiated the effect of 9.1 
on tyrosine phosphorylation. The ability of 9.1 alone to 
cause a small increase in tyrosine phosphorylation 
presumably reflects a low level of exposure of the CD2 
epitope for this antibody on unstimulated Jurkat cells. 
However this low level of activation by 9.1 alone is not 
sufficient to stimulate IL-2 production (table 1). 
The phosphotyrosine antibodies used for the blots 
are specific for phosphotyrosine. The signal in the im- 
munoblots in fig.1 was unaffected by the inclusion of 
1 mM phosphoserine or 1 mM phosphothreonine dur- 
ing the incubation with the phosphotyrosine antibodies 
while the presence of 10 /IM phosphotyrosine caused a 
complete Ioss of the signal (data not shown). 
In agreement with previous studies [9,10], stimula- 
tion of the CD3 receptor on Jurkat cells also causes in- 
creases in tyrosine phosphorylation. Fig.2 compares the 
time course and pattern of tyrosine phosphorylation in- 
duced by stimulating either the CD3 or the CD2 recep- 
tor. The pattern of tyrosine phosphorylation induced 
by CD3 antibodies is identical to that observed when 
cells are stimulated by antibodies to CD2. The tyrosine 
phosphorylation induced via the CD3 receptor was 
maximal by the earliest ime point of 2.5 min, begins to 
decline by 10 min and has almost returned to basal 
1eveIs by 40 min. In contrast the tyrosine phosphoryla- 
tion stimulated by CD2 antibodies is considerably 
slower than that seen with the CD3 antibodies, requir- 
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Fig.2. Comparison f the kinetics and patterns of tyrosine phosphorylation induced by either CD3 or CD2 antibodies. Jurkat cells were treated 
with saturating concentrations of either 0KT3 or the combination of LeuSb and 9.1 antibodies. At the indicated times in minutes the cells were 
spun down and dissolved in SDS buffer. The samples were then analyzed by immunoblots with antibodies to phosphotyrosine. The arrows indicate 
the positions of the proteins that undergo large increases in tyrosine phosphorylation. 
ing 5 to 10 min to reach a maximum. In addition the 
maximal levels of tyrosine phosphorylation seen with 
the CD2 antibodies is less than that observed with the 
CD3 antibodies. However, like activation through CD3 
the tyrosine phosphorylation nearly returned to basal 
levels after 40 min of incubation with the CD2 an- 
tibodies. 
Chronic treatment of T cells with CD3 antibodies 
such as OKT3 causes the down modulation of the CD3 
complex [21,22]. Thus if the CD2-induced tyrosine 
phosphorylation is dependent on the expression of the 
CD3 complex then down modulation of this complex 
should obliterate the effects of CD2 antibodies on 
tyrosine phosphorylation. Fig.3 shows how down 
modulation of the CD3 complex affects the ability of 
CD2 and CD3 antibodies to increase tyrosine 
phosphorylation in Jurkat cells. As expected, pretreat- 
ment of the cells with OKT3 antibodies causes a com- 
plete loss of the CD3-dependent tyrosine 
phosphorylation. Down modulation of the CD3 com- 
plex also significantly inhibited the ability of CD2 an- 
tibodies to increase tyrosine phosphorylation. An 
exception to this loss of CD2-stimulated tyrosine 
phosphorylation is a protein of molecular weight of 
65000. This protein was consistently observed to 
undergo increases in tyrosine phosphorylation in 
response to CD2 antibodies even after down modula- 
tion of CD3 resulted in a complete loss of response to 
CD3 antibodies. These results suggest that while the 
major pathway for CD2-dependent tyrosine 
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Fig.3. Effect of down modulation of the CD3 receptor on CD3- and 
CDZ-induced tyrosine phosphorylation. Jurkat cells were 
preincubated in the absence (A) or presence (B) of 0KT3 antibodies 
for 16 h. The cells were then washed and were either untreated (C), 
restimulated on the CD3 receptor with 0KT3 antibodies (CD3) or on 
the CD2 receptor with9.1 + LeuSb (CD2). Cells were incubated for 
5 min with OKT3 antibodies and 15 min with CD2 antibodies. 
Following these incubations the cells were pelleted and processed for 
immunoblots. The arrows in A indicate those proteins that undergo 
a large increase in phosphotyrosine upon stimulation of either CD3 
or CD2 while the arrowhead in B indicates the 65 kDa protein whose 
tyrosine phosphorylation still increases in response to CD2 antibodies 
after down modulation of CD3. 
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phosphoryIation is via CD3, CD2 can also stimulate 
tyrosine phosphorylation by a mechanism independent 
of CD3. 
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